Company profile

Hansoh Pharmaceutical Group

Diversified pharma

Public Market Listing

3692HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Hansoh Pharmaceutical Group are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(14 total)

14Total Assets

1Approved

5Phase 3 / Filed

8Phase 1–2 / Early

10Diseases

Showing 14 of 14 assets

		Target & Modality
Pegmolesatide (HS-20039)	Approved	Erythropoietin receptor (EPO-R)Peptide	Chronic Kidney Disease
Almonertinib	Phase 3	EGFRSmall molecule	Non-Small Cell Lung Cancer
HS-10374	Phase 3	TYK2Small molecule	Psoriatic ArthritisPsoriasis
HS-20094	Phase 3	GLP-1/GIP receptor (dual)Peptide	Obesity
HS-20137	Phase 3	IL-23 p19Monoclonal antibody	Psoriasis
PEX168No recent activity	Phase 3	GLP-1 receptorPeptide	Type 2 Diabetes
Ametinib	Phase 2	EGFRSmall molecule	Non-Small Cell Lung Cancer
HS-10353	Phase 2	GABA-A receptorSmall molecule	Major Depressive Disorder
HS-10380	Phase 2	Dopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Small molecule	Schizophrenia
HS-10390	Phase 2	Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule	Chronic Kidney Disease
HS-10509	Phase 1	—Small molecule	Schizophrenia
HS-10510	Phase 1	PCSK9Small molecule	Atherosclerotic Cardiovascular Disease
HS-10522	Phase 1	Undisclosed / early pipelineSmall molecule	Hypertension
HS-20118	Phase 1	IL-23 receptorPeptide	Psoriasis

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.